A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine. / Purpose and Background: Neuroblastomais the most common pediatric extracranialsolid tumor
•50% of patients present with metastatic disease typically involving bone and bone marrow
•Despite intensive multimodality therapy, 40% of patients with high-risk neuroblastomawill experience relapse
•131I-MIBG is an active salvage agent for relapsed and refractory MIBG-avid disease
•It is unknown whether disease progression following 131I-MIBG treatment occurs in previously involved vs. new sites of disease
•A better understanding of this pattern may inform the use of consolidative focal therapies following 131I-MIBG administration
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/627159 |
| Date | 30 March 2018 |
| Creators | Fishel Ben-Kenan, Rotem |
| Contributors | The University of Arizona College of Medicine - Phoenix, Polishchuk, Alexei MD, PhD |
| Publisher | The University of Arizona. |
| Source Sets | University of Arizona |
| Language | en_US |
| Detected Language | English |
| Type | Thesis |
| Rights | Copyright © is held by the author. Digital access to this material is made possible by the College of Medicine - Phoenix, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. |
Page generated in 0.0022 seconds